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ABSTRACT 
Objective: To investigate longitudinal fetal growth and growth velocity for commonly 
measured biometric parameters in women with chronic hypertension. 
Methods: Two centre retrospective European study of women with chronic hypertension 
ascertained at pregnancy booking. Ultrasound measurements of head circumference (HC), 
abdominal circumference (AC) and femur length (FL) were used to derive longitudinal fetal 
growth charts derived using functional linear discriminant analysis (FLDA). These were 
compared to existing cross sectional and longitudinal charts, as was birthweight. 
Results: 282 women with a median of 3 third trimester ultrasound examinations were 
included. Gestation at delivery was 37.5 weeks (SD 2.68), birthweight 3049 g (SD 785). 
Birthweight <10
th
 percentile found in 15.6% deliveries, >90
th
 percentile 20.2%. Fetal size 
curves derived from women with chronic hypertension were no different to cross sectional 
and longitudinal charts for a normal population. Compared to a standard longitudinal 
biometry chart, growth velocity (mm/day) in chronic hypertension was higher for AC and FL 
at 30-32 weeks (AC 1.447 vs 1.357 p<0.05; FL 0.296 vs 0.269 p<0.01) and 34-36 weeks (AC 
1.325 vs 1.140 p<0.01; FL 0.248 vs 0.198 p<0.01). 
Conclusions: In women with chronic hypertension there is an excess of both SGA and LGA 
babies compared to population standards. Growth velocity of the AC and FL was greater after 
30 weeks compared to a normal population. 
 
KEY WORDS: abdominal circumference, biparietal diameter, femur length, FLDA, head 
circumference 
  
LIST OF ABBREVIATIONS 
- BMI: body mass index 
- GDM: gestational diabetes mellitus 
- SGA: small for gestational age 
- LGA: large for gestational age 
- HC: head circumference 
- AC: abdominal circumference 
- FL: femur length 
- BPD: biparietal diameter 
- FLDA: functional linear discriminant analysis 
- US: United States 
- UK: United Kingdom 
 
KEY MESSAGE 
In chronic hypertensive pregnant women fetal growth patterns differ from those of 
uncomplicated pregnancies. 
  
FETAL SIZE AND GROWTH VELOCITY IN CHRONIC HYPERTENSION 
INTRODUCTION 
Chronic hypertension affects up to 5% of pregnancies, but recent demographic analysis 
suggests that its incidence is increasing. Reasons for this include maternal age, the increasing 
tendency of women with chronic disease becoming pregnant, obesity and women with one or 
more of these attributes having access to assisted reproduction techniques.  
Chronic hypertension is associated with an increased risk of maternal and fetal complications. 
A recent meta-analysis of 795221 cases of chronic hypertensive pregnancies reported the 
incidence of superimposed preeclampsia to be 29%, Cesarean delivery 42% and perinatal 
death rate of 3-5%. Adverse perinatal outcomes are secondary to placental abruption, preterm 
birth (33%) and birth weight below 2500 g (22%) (1,2). Poor pregnancy outcome is not 
related to a particular threshold of blood pressure nor to the degree of blood pressure control. 
Apart from some beta blockers, antihypertensive drugs are not associated with a higher 
incidence of growth restriction or poor perinatal outcome (3,4). 
Women with chronic hypertension invariably attend more frequently for ultrasound scans of 
the fetus, principally to check growth. In the United Kingdom, National Institute of Clinical 
Excellence (NICE) guidance suggests third trimester ultrasound scans in view of the risk of 
fetal growth restriction in pregnancies (5) and this advice is ubiquitous in other national 
guidelines included that of the American College of Obstetricians and Gynecologists (6). 
There is growing debate about appropriate reference values for fetal growth in healthy 
women, with controversy between those reporting similar fetal growth irrespective of 
geographical location (7) and those finding small differences between populations (8). 
Similarly, there is no reliable data relating to fetal growth in women with chronic 
hypertension; all assumptions are back-calculated from birthweight. We do not advocate the 
  
use of fetal size charts customized for maternal pathological condition, but such data may be 
useful in understanding how growth differs compared to normal. 
The aim of this study of pregnant women with chronic hypertension was to determine whether 
fetal growth velocity deviates from normal in the third trimester by comparing fetal size at 
different gestation points (longitudinal growth) to widely used reference charts. From this, we 
planned to derive growth velocity as the derivative of change in size with respect to time 
(dx/dt), comparing this to an established longitudinal fetal growth velocity chart to determine 
if and at which gestation point growth velocity deviates from normal. 
  
METHODS 
This was a database search of all pregnant women with a singleton pregnancy and known 
diagnosis of chronic hypertension before pregnancy or of hypertension before 20 weeks of 
gestation. Data were collected from the Rosie Maternity Department at Addenbrooke’s 
Hospital in Cambridge, UK, between January 2002 and December 2011 which over the study 
period had approximately 5000 births annually and from Fetal-Maternal Unit in Spedali Civili 
of Brescia, Italy, between January 2008 and December 2012 which had approximately 4000 
births yearly.  
All pregnancies underwent first trimester ultrasound and an ultrasound scan at 19-21 weeks of 
gestation and the frequency of third trimester ultrasound scans was according to local 
protocols. Age, parity, ethnicity, BMI, smoking, alcohol consumption, significant comorbidity, 
pharmacological therapy, delivery data including gestational age at delivery and outcome of 
pregnancy, birthweight, sex of the fetus, delivery type, Cesarean section indications, Apgar 
score, NICU admission were collected. Women with additional comorbidities such as 
Systemic Lupus Erythematosus or chronic kidney disease were not included. For each scan, 
we collected fetal biometric parameters including the head circumference (HC), the 
abdominal circumference (AC) and the femur length (FL), while  
In Cambridge, ultrasound biometry data were collected using the Rosie Maternity Hospital’s 
software, Protos® and Astraia
©
 for ultrasound data; in Brescia from the Materno-Fetal 
software, Viewpoint®. For the few patients who did not deliver at the Spedali Civili di 
Brescia data related to the outcome of pregnancies were collected from the hospitals where 
the patients delivered. Data were entered on a separate database with restricted access on the 
hospital servers and fully anonymised prior to analysis. 
  
The Cambridge research ethics committee advised that analysis and publication of routinely 
collected, fully anonymised obstetric growth measurements entered into an ultrasound 
software system as part of normal clinical management did not require approval. 
Maternal age, BMI and parity for the chronic hypertension group were compared between the 
chronic hypertensive women and a control population (9), using either a Pearson's chi-square 
test (BMI group and parity) or a Fisher's exact test (maternal age group). 
At least 2 scans per case were required for growth curve creation; women with AC, HC and 
FL measurements at only 1 time point were dropped, leaving 223 cases. Longitudinal growth 
curves were then created using Functional Linear Discriminant Analysis software (10). After 
the calculation of the growth curve, we restricted comparisons between the chronic 
hypertension group and the normal population (9) to be between 20 and 36 weeks due to the 
sparsity of the data outside of this time period. Empirical p-values were then calculated at 9 
time points, starting at 20 weeks and increasing at 2 week intervals, to test for differences in 
growth between the chronic hypertensive group and the control population. 
Growth curves for fetal biometry were created using regression methods outlined in Verburg, 
2008 (11). Each scan is assumed to be an independent observation, and so the sample sizes for 
AC, HC and FL respectively were 824, 816 and 823. We used these curves to calculate the 
growth velocities for each measurement type (AC, HC, FL) between 26-28 weeks, 30-32 
weeks and 34-36 weeks. The growth curves for a normal population from Verburg et. al., 
2008 (11) were used as the controls. Empirical p-values were calculated for each time 
interval, and for each measurement type, to test if the growth velocities of the chronic 
hypertension cases differed to those of the control population. 
For a given measurement type and time interval a sample of normal growth velocities was 
generated (sample sizes for AC, HC and FL analysis were as above). The mean growth 
  
velocity was recorded and this was repeated 10,000 times. The resulting distribution of 
expected growth velocities for the normal population was then used to calculate the empirical 
p-value. This is the number of values more extreme than the chronic hypertension group mean 
divided by the number of values available (10,000 in this case). 
Using equations derived by Hadlock et. al., 1991 (12), we calculated the birthweight 
percentile for each hypertensive case using 'normal' pregnancy inputs. This allowed us to 
compare gestational-age adjusted birthweights of the chronic hypertensive and normal 
populations by looking at hypertension birthweights as a percentile of the normal population 
birthweight distribution. Inputs used were mean birth weight at 40 weeks for a normal 
population and standard deviation (3400 g and 449.79 g, respectively) (9). If there was no 
difference between the birth weights of the hypertensive population and the control 
population then we would expect to see an approximately uniform distribution for the 
calculated birthweight percentiles. The proportion of small for gestational age (SGA) and 
large for gestational age (LGA) babies from chronic hypertensive mothers were then 
compared to the expected proportions from the control population (11) using empirical p-
values. 
For a normal population we would expect the birthweight percentile distribution to be 
uniform. 282 normal pregnancy birthweight percentiles were generated, and the proportion of 
SGA cases (birthweight percentile < 10th percentile) and LGA cases (birthweight percentile > 
90th percentile) were recorded. This was repeated 10,000 times so that we generated 
distributions for the proportion of SGA babies and LGA babies from normal pregnancies 
when the sample size = 282. The empirical p-value is then the proportion of values more 
extreme than that observed in the chronic hypertension group. 
 
  
RESULTS 
Two hundred and eighty two chronic hypertensive women were analyzed whose demographic 
data are shown in Table 1. Of 282 women 134 (48%) were on antihypertensive therapy: 79 
were taking calcium antagonists, 29 beta blockers, 7 alpha-methyldopa, 16 combination 
therapy and 3 other treatments. 
282 women were with 1-6 scans were included. For the purposes of growth and growth 
velocity assessment, we analyzed the data from 223 women who had at least 2 scans (Table 
2). Figure 1 shows the birth weight percentile distribution within the study group and the 
expected birth weight percentile distribution in the reference population. Figures 2a, 3a and 4a 
show the scatter plots for AC, HC and FL in 223 women. Figures 2b, 3b and 4b demonstrate 
the FLDA derived growth percentiles compared to the cross-sectional reference fetal growth 
charts. No differences were found for fetal AC, HC and FL 50
th
 percentile between the FLDA 
and reference chart at any gestational time points.  
HC and AC are normally distributed at the 3 time points where most measurement data are 
available according to a Shapiro-Wilks and an Andersen-Darling test for normality. There is 
evidence that FL is non-normal at 20 and 24 weeks according to these 2 tests but the 
distribution histograms allow the data to be analysed assuming normality (Supplementary 
Figure 5). 
Table 3 shows the growth velocity for AC, HC and FL for the normal population based on 
reference charts and those with chronic hypertension. There were no differences between the 
three growth parameters at 26-28 weeks. For both later time points 30-32 and 34-36 weeks, 
AC and FL growth velocity was greater in the chronic hypertension group compared to 
growth velocities in a normal population. 
  
Delivery outcomes are detailed in table 1. The mean gestation at delivery was 37.5 weeks (SD 
2.78) and birth weight 3049 g (SD 785) was similar in the two centers. Forty-eight percent of 
all deliveries were by cesarean section. The incidence of superimposed preeclampsia was 
12.8%, gestational diabetes 12% and of stillbirth was 0.7%. 
Demographic and delivery data were compared with a recently reported and independent UK 
reference pregnant population (9). The age distribution for hypertensive women is older, with 
50.5% being > 35 years compared to >16% for the reference population  (Fisher’s exact test 
p<0.01) ; parity greater with fewer para 0 and more para ≥1 women (Pearsons Chi square 
p<0.01) and higher BMI with 16% BMI ≥35 compared to 7.5% (Pearsons Chi square test 
p<0.01).  
Within the same group birthweight <10
th
 percentile and >90
th
 percentile were found in 15.6% 
and 20.2% of the deliveries respectively, this being different to the proportion expected based 
on the comparator population (p 0.045 and p <0.01, respectively). When women with GDM 
were excluded, the proportion of birthweight <10
th
 percentile was 14.3% and birthweight 
>90
th
 percentile was 17.2%, again different to the comparator population (p=0.016 and p<0.01 
respectively). When compared to a Scottish birth cohort (13), there was a significant excess of 
obese and morbidly obese women in all three birthweight groups SGA, normal and LGA 
(Fisher’s exact p<0.0001). 
  
DISCUSSION 
Fetal size and growth velocity have been little studied in maternal or fetal disease. Hence our 
aim in this study was not to construct ‘normal’ curves for women with chronic hypertension, 
but to investigate birth weight and growth velocity in this condition and to compare with what 
is already known in a normal population. This approach is methodologically different to 
customization as we describe fetal growth and birthweight in maternal pathology, observing 
the influences on growth and birthweight but not attempting to adjust for these. A similar 
approach has been recently reported for fetal growth in gastroschisis (1). 
We report that mean birthweight is no different in women with chronic hypertension, 
although babies weighing <10
th
 and those weighing >90
th
 percentile are significantly over-
represented, the latter particularly so. Of note is that just under half the women were on anti-
hypertensive agents but their birthweight was no different to those of the cohort overall. 
Furthermore, based on data from repeat ultrasound examinations in over 200 women, fetal 
cross-sectional biometry in the third trimester of pregnancy is no different in chronic 
hypertension compared to cross sectional ultrasound standards. However, growth velocity 
(defined as change in size with time, rather than absolute size) for the fetal abdomen and 
femur is greater in women with chronic hypertension after 30 weeks compared to that 
expected in a normal population. Hence though overall in-utero fetal size is no different in 
chronic hypertension compared to widely used normal ranges, the percentile ranges that we 
observe in chronic hypertension are wider than those of the standard charts in the third 
trimester 
A strength of the study is that all cases of chronic hypertension were ascertained prior to 20 
weeks and followed throughout pregnancy in both units. We therefore did not include patients 
in whom a retrospective diagnosis of chronic hypertension was given. Perhaps for these 
  
reasons, the proportion of chronic hypertensive pregnancies that we report in our population 
of approximately 0.4% is lower than the 1.3% reported for a US population ascertained at 
delivery (15). There is no reason why this should have biased the data though it is possible 
that the better than expected pregnancy outcomes with a superimposed preeclampsia risk of 
12.8% and stillbirth risk 0.7% were because the women were closely monitored from the first 
trimester onwards (4,16). 
The maternal characteristics of our population of women with chronic hypertension were 
different to a normal population: they had higher maternal age, parity and BMI compared to 
an unselected booking population from the West Midlands of the UK in the same period 
(9,17). Though none of the women had pre-existing insulin dependent diabetes, 12% (33/280) 
developed gestational diabetes which is more frequent than the general population incidence 
of 7% reported for a US population (15). Excluding women with GDM did not alter the 
findings of an excess in both <10
th
 percentile and >90
th
 percentile babies.  
Women with hypertension and diabetes are more likely to have a raised BMI and be older; 
this is the case in the cohort that we recruited but we did not customize birth weight for 
maternal factors. Whilst the significantly increased BMI in this population of hypertensive 
women (across all birthweight percentiles) might explain at least partly the increased 
incidence of birthweight >90
th
 percentile, the same explanation cannot be put forward to 
explain the increase in babies weighing <10
th
 percentile. 
The question of whether birth weight customization is appropriate is now particularly topical 
in the context of the findings from the Intergrowth study (7). This study had strict criteria 
resulting in only around 35% of all women being eligible for their ultrasound data to be used 
for construction of the charts. All of our cases, being hypertensive, would have been excluded 
from the Intergrowth study. Our data have instead been transposed onto the most widely 
  
available cross sectional growth charts (11) and growth velocity has been derived from the 
only population based longitudinal growth charts from which growth velocity as opposed to 
fetal size at a given gestation can be calculated (18). The methodology that we have employed 
to develop fetal HC, AC and FL biometry charts is different to that used in the original 
development of the standard charts widely used for cross sectional ultrasound biometry (10). 
Using this methodology (functional linear discriminant analysis: FLDA), the use of all fetal 
size datapoints in a combined spline curve does not allow the cases with the most 
observations, and perhaps the most severe disease phenotype, undue influence over the final 
model. The FLDA technique has been reported for first trimester longitudinal size (19) and 
fetal growth in gastroschisis and growth restriction (14). The advantage of FLDA is that it is 
robust for a dataset of women where cases have repeated measures which are irregularly 
spaced and varying in number as all are converted to individual curves. To derive fetal growth 
velocity curves for the purposes of our comparisons, at least two observations per women 
were required. 
An excess of small for gestational age babies has been reported in women with chronic 
hypertension (1, 16) which has been taken to imply that fetal growth must also be impaired. 
From this assumption has arisen recommendations for increased ultrasound surveillance of 
these pregnancies (3, 20). To our knowledge, no studies have considered actual fetal growth 
in chronic hypertension as opposed to inferring it from cohort studies of birthweight.  
We found that both SGA and LGA babies are over-represented compared to a normal birth 
weight distribution. This has not been previously appreciated and is unlikely to be a chance 
observation as we also report an increase in growth velocity for the fetal abdomen and femur 
after 30 weeks. These findings might be explained at least in part by the higher incidence of 
gestational diabetes and the greater BMI in this population consistent with the hypothesis that 
an underlying metabolic disorder is more common in chronic hypertensive patients. 
  
It is possible that chronic hypertension in pregnancy is associated with pre-existing maternal 
characteristics that affect fetal growth and potentially neonatal wellbeing. A recent meta-
analysis showed that the relative risk for delivery of a <2.5kg baby was 2.7 for women with 
chronic hypertension though the relative risk for perinatal death was 4.2 (1) however this 
study did not consider the equivalent relative risks for delivery of a large baby. Our results 
raise the question as to whether the increased perinatal risks associated with chronic 
hypertension are indeed purely due to fetal growth impairment.  
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Figure 1: Histogram showing the distribution of the birthweight centile within the hypertension (HT) 
group and the expected distribution within the control group (in Blue). 
 
 
 
 
 
 
 
  
  
Figure 2 (a) Abdominal circumference scatter diagram (b) transformation by FLDA onto cross sectional 
charts (Chitty)  
 
 
  
  
Figure 3 (a) Head circumference scatter diagram (b) transformation by FLDA onto cross sectional charts 
(Chitty)  
 
 
 
  
Figure 4 (a) Femur length scatter diagram (b) transformation by FLDA onto cross sectional charts (Chitty) 
(c)  
 
 
 
 
 
  
Figure 5 (Suppelementary) – Distribution histograms of the femur length (FL) at 20 and 24 weeks. 
21.  
  
Table 1 Clinical and demographic data and pregnancy outcomes 
(n=282 unless otherwise stated) 
Maternal age 
(years; mean ± SD) 
34 ± 5 
Maternal BMI 
(mean ± SD; n=258) 
28 ± 7 
Maternal ethnicity  
(n=281) 
White European 78 % 
African-Caribbean 11% 
Asian 11% 
Maternal parity 
(Median, range; n=278) 
1 (0-6) 
Smoking 
(n=278) 
4.3% 
Regular Alcohol use 
(n=278) 
5.3% 
Gestational age at delivery 
(weeks; mean ± SD) 
37.5 ± 2.78 
Deliveries before 34 weeks n=11    3.9% 
Deliveries before 37 weeks n=37  13.1% 
Birthweight (g) 3049 ± 785 
SGA < 10th percentile 15.6% 
LGA >90th percentile 20.2% 
Delivery type 
Caesarean 48% 
Vaginal Delivery 52% 
Fetal Sex Male 51%  
Stillbirths (n=2) 0.7% 
Median Apgar score at 5 minutes 9 
NICU admission (n=46)      16.3% 
Gestational Diabetes (n=33 )      12% 
Preeclampsia (n=36)      12.8% 
HELLP (n=3)       1.1% 
 
  
  
Table 2: Number of ultrasound biometry measurements for abdominal circumference (AC), head 
circumference (HC) and femur length (FL). 
 
 
Measurement type 
Number of cases with number of scans available Total number of 
cases 
2 scans 3 scans 4 scans 5 scans 6 scans 
AC 52 67 58 35 11 223 
HC 55 65 60 33 10 223 
FL 52 67 58 35 11 223 
  
  
Table 3: Growth Velocity for AC, HC and FL (mm/day) 
*p <0.05 compared to the corresponding value for the normal population 
#p <0.01 compared to the corresponding value for the normal population 
 
 Parameter 
26-28 
weeks 
30-32 
weeks 
34-36 
weeks 
Normal population  
(derived from Verburg UOG 2008) 
  
  
AC 1.526 1.357 1.140 
HC 1.466 1.177 0.826 
FL 0.332 0.269 0.198 
Chronic hypertension  
  
  
AC 1.530 1.447* 1.325# 
HC 1.425 1.177 0.874 
FL 0.338 0.296# 0.248# 
 
  
 
HIGHLIGHTS 
 Mean birthweight is no different in women with chronic hypertension 
 SGA and LGA babies are significantly over-represented in hypertensive pregnancies 
 Growth velocity of the abdomen and femur is greater in hypertensive women 
 Wider percentile ranges can be found in chronic hypertension 
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